
Valitse etikettisi
näkyy suoraan injektiopullossaEmpagliflozin (Jardiance)
Medication
- Lähetetään Saksasta
Tilaus
- DHL seurannalla
- Huomaamaton pakkaus
Yhdellä silmäyksellä
Empagliflozin (Jardiance) lukuina
Tietopankkimme keskeiset luvut. Vedä pistettä käyrää pitkin nähdäksesi, paljonko yhden annoksen jälkeen on laskennallisesti jäljellä.
Koko tietopankkiartikkeliHow long does it stay in the body?
Share left after one dose, calculated with a half-life of ~12 hours
Simplified model without an absorption phase, half-life from the TPD lexicon.
Half-life
about12hours
effect lasts 24h
- Class
- SGLT2 inhibitorselective, oral
- Use
- Oralonce daily in the morning
- Sizes
- 10 to 25 mg2 sizes in the shop
What studies show
All 5 sources in the lexicon- Zinman et al., NEJM, 2015
- Packer et al., NEJM, 2020
- Anker et al., NEJM, 2021
Arvostelut
Mitä asiakkaat sanovat
Vain todelliset tilaukset, joissa oli Empagliflozin (Jardiance).
Kaikki arvostelutTuotteelle Empagliflozin (Jardiance) ei ole vielä laboratorioanalyysia. Äänestä sitäTestauta itse, me maksamme puoletKaikki laboratorioanalyysit
Tietoa
Kaikki aiheesta Empagliflozin (Jardiance)
Tarkemmat tiedot tulossa pian.
Is empagliflozin approved?
Yes. In the USA it has been marketed as a prescription drug since 1 August 2014. According to the label for type 2 diabetes, to reduce cardiovascular death in diabetes with cardiovascular disease and in heart failure. It is not recommended in type 1 diabetes because of the ketoacidosis risk.
How does empagliflozin work?
It blocks SGLT2 in the kidney, the transporter that takes sugar back from the urine. In a cell assay a concentration of 3.1 nM was enough for half-maximal inhibition. Of all inhibitors tested it was the most selective over the gut transporter SGLT1. The sugar is lost with the urine, independently of insulin.
What did EMPA-REG OUTCOME show?
7,020 people with type 2 diabetes and cardiovascular disease were followed for a median of 3.1 years. The primary outcome of cardiovascular death, heart attack and stroke fell from 12.1 to 10.5 percent. Cardiovascular deaths fell by 38 percent, hospitalisations for heart failure by 35 percent and deaths from any cause by 32 percent. Heart attack and stroke did not differ significantly.
Does it also work without diabetes?
In heart failure, yes. In EMPEROR-Reduced and EMPEROR-Preserved the effect was the same with and without diabetes, likewise in chronic kidney disease in EMPA-KIDNEY. With reduced ejection fraction kidney function fell by 0.55 instead of 2.28 ml per minute per year.
What is euglycaemic ketoacidosis?
Acidification of the blood by ketone bodies while blood sugar is normal or only slightly raised. On SGLT2 inhibitors the typical warning sign of high sugar is therefore missing. The medical literature describes it as a predictable, detectable and preventable risk of the drug class.
Which side effects have been described?
In EMPA-REG OUTCOME only genital infections were more common than on placebo. In EMPEROR-Reduced uncomplicated genital infections were more common, in EMPEROR-Preserved also urinary tract infections and low blood pressure. In EMPA-KIDNEY serious adverse events were equally common in both groups.
Liittyvät
Samankaltaiset tuotteet
Telmisartan
Lääkkeet · Sydän ja verisuonet Sydän ja verisuonet
2 kokoa
Laboratoriotestattu
Ivermectin
Lääkkeet · Vatsa ja maksa Vatsa ja maksa
1 koko
Fenbendazol
Lääkkeet · Vatsa ja maksa Vatsa ja maksa
1 koko
Prednisone
Lääkkeet · Vatsa ja maksa Vatsa ja maksa
1 koko
Empagliflozin (Jardiance)